Kurzfassung

Risk-stratified sequential treatment of post-transplant lymphoproliferative diseases with 4 courses of rituximab SC followed by 4 courses of rituximab SC, 4 courses of rituximab SC combined with CHOP-21 or 4 courses of rituximab SC combined with alternating CHOP-21 and DHAOx